While p38 MAPK inhibitors have shown potential to prevent progression of Aβ and tau pathology in AD, they can cause side effects and can cross‐react with other kinases, limiting their clinical usefulness (Kheiri et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.